the sun malaysia ipaper logo 150x150
Friday, July 3, 2026
27.5 C
Kuala Lumpur
the sun malaysia ipaper logo 150x150

Bandai Namco demands better QC

HARD times call for harder decisions, with Bandai Namco’s recent financial report revealing that the company has suffered an 8.9% drop in net sales for its third fiscal quarter ended December 2023, along with a 96.5% drop in income.

The drop in profit was apparently due to the exponential sales of 2022’s Elden Ring. The numbers that the game made were never replicated by any other title in the subsequent year. The company has thus enforced tighter quality control for all in-development games.

Following the report, a Q&A was published with a company representative, which confirmed that the games were cancelled due to a “loss on disposal” and “internal rules regarding evaluation”, according to Video Games Chronicle’s translation.

Bandai Namco views the changes as necessary due to the longer development period for games in this era, while also factoring how long turning in a profit would take based on how much was invested during each game’s development period.

Despite the doom and gloom, the company views the recent Tekken 8 as a success. Being both well-received by fans of the fighting game genre and praised by critics (it is universally acclaimed on Metacritic), Tekken 8 has sold over two million copies since release.

On the bright side, Bandai Namco revealed that work continues on the highly anticipated expansion to Elden Ring, which it is preparing for release, along with a new Dragon Ball game.

STAY AHEAD OF THE CURVE

Join our community for instant updates and exclusive content.

Join Telegram Channel

Related


spot_img

Latest News

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations

TAIPEI, TAIWAN - Media OutReach Newswire - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX) including its biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of US $122.5 million through its wholly owned subsidiary Bora Biologics USA, LLC.. Upon closing, Bora signed a long-term CDMO Service Agreement with MacroGenics.

Most Viewed

spot_img
WC26

World Cup 2026

Updates, Fixtures, Results & Standings